Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs

This work was partially supported by grants from the Japan Society for the Promotion of Science for M Kitada (24591218), TN (24659264), KK (23790381), DK (25282028, 25670414, and research grants from the Japan Research Foundation for Clinical Pharmacology to K.K. (2011), and Takeda visionally research grant to K.K. (2013). This work was partially supported by a Grant for Collaborative Research awarded to DK (C2011-4, C2012-1) and a Grant for Promoted Research awarded to KK (S2011-1, S2012-5) from Kanazawa Medical University. KK was also supported by several foundational grants, including grants from the Japan Research Foundation for Clinical Pharmacology, the Daiichi-Sankyo Foundation of Life Science, the Ono Medical Research Foundation, the NOVARTIS Foundation (Japan) for the Promotion of Science, the Takeda Science Foundation, and the Banyu Foundation. KK and DK received lecture fees from Both Boehringer Ingelheim, Eli Lilly, and Mitsubishi Tanabe Pharma. Boehringer Ingelheim, Eli Lilly, and Mitsubishi Tanabe Pharma donated to Kanazawa Medical University and were not directly associated with this project. JG is supported by a grant from the National Institutes of Health (R01HL131952).